BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US

被引：0
|
作者：
Sandin, R. [1 ]
Veenstra, D. [2 ]
Dzingina, M. [3 ]
Vankelegom, M. [4 ]
Sullivan, S. [2 ]
Campbell, D. [5 ]
Ma, C. [4 ]
Harrison, C. [4 ]
Draica, F. [6 ]
Wiemken, T. L. [6 ]
Mugwagwa, T. [6 ]
机构：
[1] Pfizer AB, Stockholm, Sweden
[2] Curta Inc, Seattle, WA USA
[3] Pfizer, London, England
[4] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[5] Curta Inc, S Kingstown, RI USA
[6] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE644
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [21] In-Hospital Disease Progression in Moderate to Severe Chronic Kidney Disease Patients with COVID-19 Treated with Nirmatrelvir/Ritonavir
    Ashruf, Omer S.
    Orozco, Zara
    Haq, Imad
    Khanam, Razwana
    Ashruf, Zaid
    Kaelber, David C.
    Raina, Rupesh
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2025, 40 (02) : 501 - 504
  • [22] Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk
    Paraskevis, Dimitrios
    Gkova, Maria
    Mellou, Kassiani
    Gerolymatos, Gerasimos
    Psalida, Naya
    Gkolfinopoulou, Kassiani
    Kostaki, Evangelia-Georgia
    Loukides, Stylianos
    Kotanidou, Anastasia
    Skoutelis, Athanasios
    Thiraios, Eleftherios
    Saroglou, Georgios
    Zografopoulos, Dimitrios
    Filippou, Dimitrios
    Mossialos, Elias
    Zaoutis, Theoklis
    Gaga, Mina
    Tsiodras, Sotirios
    Antoniadou, Anastasia
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (12): : 1667 - 1674
  • [23] Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
    Akinosoglou, Karolina
    Schinas, Georgios
    Gogos, Charalambos
    VIRUSES-BASEL, 2022, 14 (11):
  • [24] Nirmatrelvir/ritonavir well tolerated for COVID-19 in patients with CKD
    Reactions Weekly, 2023, 1969 (1) : 12 - 12
  • [25] Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
    Xu, Ping
    Zhang, Lijun
    Wu, Qingguo
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [26] Nirmatrelvir mitigates the Risk of Progression in Patients with symptomatic COVID-19 Infection
    Simon, Annika
    PNEUMOLOGIE, 2022, 76 (10):
  • [27] Nirmatrelvir/ritonavir combination against COVID-19
    McDonald, Emily G.
    Lee, Todd C.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (09) : E365 - E366
  • [28] Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
    Hammond, Jennifer
    Leister-Tebbe, Heidi
    Gardner, Annie
    Abreu, Paula
    Bao, Weihang
    Wisemandle, Wayne
    Baniecki, MaryLynn
    Hendrick, Victoria M.
    Damle, Bharat
    Simon-Campos, Abraham
    Pypstra, Rienk
    Rusnak, James M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15): : 1397 - 1408
  • [29] VV116 or Nirmatrelvir- Ritonavir for Oral Treatment of Covid-19
    Edwards, Jonathan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (25): : 2395 - 2396
  • [30] BUDGET IMPACT ANALYSIS OF ORAL TREATMENT WITH NIRMALTREVIR plus RITONAVIR FOR COVID-19 IN ARGENTINA
    Chen, M.
    Zachry, W.
    Afolabi, M.
    Aweh, G.
    Chopra, I
    VALUE IN HEALTH, 2023, 26 (12) : S145 - S145
12345